AstraZeneca aims to transform cancer treatment and advance clinical practice with data presented at ESMO 2020

AstraZeneca aims to transform cancer treatment and advance clinical practice with data presented at ESMO 2020

AstraZeneca will present new developments in pursuit of its ambition to eliminate cancer as a cause of death at the European Society for Medical Oncology (ESMO) Virtual Congress 2020, 19 to 21 September.

AstraZeneca medicines and pipeline molecules feature in 114 abstracts at ESMO, a record for the Company, including 20 oral presentations and two Presidential Symposia. The data highlight the breadth of the portfolio of cancer medicines and the early-stage pipeline. Whether it is by treating cancer early or by developing tailored medicines across all stages of disease, these data have the potential to transform patient outcomes and survival.

Key presentations include:

Practice-changing overall survival (OS) data from the PROfound Phase III trial presented in a Presidential Symposium confirming the long-term benefit of Lynparza (olaparib) in biomarker-selected patients with metastatic castration-resistant prostate cancer (mCRPC)
Exploratory data from the ADAURA Phase III trial showing further support for the unprecedented patient benefit of Tagrisso (osimertinib) in the adjuvant treatment of epidermal growth factor receptor-mutated (EGFRm) non-small cell lung cancer (NSCLC) also presented in a Presidential Symposium
Data from the PACIFIC Phase III trial in unresectable Stage III NSCLC and the CASPIAN Phase III trial in extensive-stage small-cell lung cancer (ES-SCLC), two late-breaking presentations strengthening the Company’s leadership in the treatment of lung cancer
José Baselga, Executive Vice President, Oncology R&D, said: “The data being presented at ESMO will reshape clinical practice in the months and years ahead. The final PROfound overall survival data show the power of biomarker-directed medicines in prostate cancer, while the ADAURA and PACIFIC data reflect our continued focus on early detection, interception and treatment of cancer. We continue to work with urgency throughout this extraordinary period to accelerate the development of medicines in our pipeline, turning innovative science into improved outcomes for patients.”

Dave Fredrickson, Executive Vice President, Oncology Business Unit, said: “Our data at ESMO reflect our vision to transform the cancer treatment landscape, achieving more durable outcomes, treating with curative intent, and changing what it means to live with and beyond a cancer diagnosis. Our ability to detect and treat cancer early is key in bringing new treatment options to later stages of disease. We are eager to translate our pivotal research into clinical practice and help patients live better, longer lives.”

Read Full Story here